Modulation of Cerebral Blood Flow Using Quercetin, a Nutritional Supplement

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

106 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-06-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out if quercetin can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Quercetin on Metabolic Health

NCT05297032

Quercetin Lipid Metabolism Aging

TERMINATED NA

Palmitic Acid and Human Microvascular Function

NCT06683534

Microvasculature Microvascular Dysfunction Cardiovascular Diseases +3 more

NOT_YET_RECRUITING PHASE2

Effects of Quercetin on Cardiometabolic Outcomes

NCT06230861

Cardiometabolic Syndrome

RECRUITING NA

Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure (FLAVO)

NCT01691404

Hypertension Endothelial Dysfunction

COMPLETED NA

Quercetin in Coronary Artery By-pass Surgery

NCT04907253

Coronary Artery Disease

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Problem of Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

healthy young

Group Type EXPERIMENTAL

quercetin/placebo

Intervention Type DIETARY_SUPPLEMENT

Quercetin 500mg once per day versus placebo

healthy old

Group Type EXPERIMENTAL

quercetin/placebo

Intervention Type DIETARY_SUPPLEMENT

Quercetin 500mg once per day versus placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

quercetin/placebo

Quercetin 500mg once per day versus placebo

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy volunteers between the ages of 18-75 years old

Exclusion Criteria

* subjects taking vasoactive medications
* hypertension or vascular disease
* asthma
* smokers
* pregnant women
* cancer
* diabetes mellitus
* history of seizures
* history of stroke or head trauma
* subjects taking digoxin, cyclosporine,felodipine, estradiol, or quinolone antibiotics
* poor transcranial Doppler insonation windows

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes